Role of Low-Dose Infliximab for Inflammatory Complications of Central Nervous System Tuberculosis: A Retrospective Cohort Study
We evaluated low-dose infliximab (5 mg/kg) as adjunctive therapy in 20 patients with severe central nervous system tuberculosis. At 3 months, 60% achieved disability-free survival (modified Rankin Scale ≤ 2), and 75% showed clinically meaningful improvement. Our outcomes matched reports of high-dose infliximab. Randomized trials to optimize dosing are needed.
Authors
- Gigi Varghese (ORCID: https://orcid.org/0000-0001-6733-9189)
- Harshad Arvind Vanjare (ORCID: https://orcid.org/0000-0002-4321-7221)
- Prabhakar Thirumal Appaswamy
- Rajiv Karthik
- Selwyn Selva Kumar D
- Dr Abi Manesh
- Dr Nishi Somarkutty
- Joy Sarojini Michael
- Priyanka Gautam
- Jayavelu Hariram Prasad D
- Veerasamy Nagaraj
Institutions
- Christian Medical College, Vellore (IN)
- Christian Medical College (IN)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1093/cid/ciaf573
- Primary Topic
- Infectious Diseases and Tuberculosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00